01244.HK
3D Medicines Inc.
HKSE · Healthcare · Biotechnology · CN
HKD 2.61
+3.98%Year over year
Reported trailing growth
- Revenue
- -20.2%
- EBITDA
- +13.0%
- EBIT
- +24.4%
- EPS
- -4.4%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -14.4%
- EBITDA
- +8.8%
- EBIT
- +8.7%
- Net income
- +2.8%
- EPS
- +4.0%
- Free cash flow
- +40.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026